Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis.
Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM. Lenk L, et al. Among authors: den boer ml. Blood. 2024 Mar 22:blood.2023021088. doi: 10.1182/blood.2023021088. Online ahead of print. Blood. 2024. PMID: 38518105 Free article.
High expression of CD40 on B-cell precursor acute lymphoblastic leukemia blasts is an independent risk factor associated with improved survival and enhanced capacity to up-regulate the death receptor CD95.
Troeger A, Glouchkova L, Ackermann B, Escherich G, Meisel R, Hanenberg H, den Boer ML, Pieters R, Janka-Schaub GE, Goebel U, Laws HJ, Dilloo D. Troeger A, et al. Among authors: den boer ml. Blood. 2008 Aug 15;112(4):1028-34. doi: 10.1182/blood-2007-11-123315. Epub 2008 Jun 13. Blood. 2008. PMID: 18552209 Free article.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.
van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, van der Velden VH, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP, Den Boer ML. van der Veer A, et al. Among authors: den boer ml. Blood. 2013 Oct 10;122(15):2622-9. doi: 10.1182/blood-2012-10-462358. Epub 2013 Aug 23. Blood. 2013. PMID: 23974192 Free PMC article.
IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, Pieters R, Biondi A, Valsecchi MG, Stanulla M, den Boer ML, Cazzaniga G. van der Veer A, et al. Among authors: den boer ml. Blood. 2014 Mar 13;123(11):1691-8. doi: 10.1182/blood-2013-06-509794. Epub 2013 Dec 23. Blood. 2014. PMID: 24366361 Free article.
Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia.
van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML. van der Veer A, et al. Among authors: den boer ml. Blood Cancer J. 2014 Feb 14;4(2):e181. doi: 10.1038/bcj.2014.5. Blood Cancer J. 2014. PMID: 24531445 Free PMC article. No abstract available.
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM, Steeghs EM, Marchante JR, Boeree A, Beaudoin JJ, Beverloo HB, Kuiper RP, Escherich G, van der Velden VH, van der Schoot CE, de Groot-Kruseman HA, Pieters R, den Boer ML. Boer JM, et al. Among authors: den boer ml. Oncotarget. 2017 Jan 17;8(3):4618-4628. doi: 10.18632/oncotarget.13492. Oncotarget. 2017. PMID: 27894077 Free PMC article.
190 results